- Home
- VRDN
as 07-26-2024 4:00pm EST
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $31.56 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.93 - $24.18 | Next Earning Date: | 08-06-2024 |
| Revenue: | $288,000 | Revenue Growth: | -82.59% |
| Revenue Growth (this year): | 12.5% | Revenue Growth (next year): | -54.95% |
Stock Insider Trading Activity of Viridian Therapeutics Inc. (VRDN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | VRDN | Director10% Owner | Jan 22 '24 | Buy | $21.00 | 476,190 | $9,999,990.00 | 1,839,954 | SEC Form 4 |
Latest Viridian Therapeutics Inc. News
VRDN Breaking Stock News: Dive into VRDN Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
Business Wire
24 days ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
Business Wire
2 months ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
Business Wire
3 months ago
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
Simply Wall St.
3 months ago
Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
3 months ago
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Compare VRDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.